Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?

被引：1
|
作者：
Del Prato, Stefano [1 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Sect Diabet & Metab Dis, I-56124 Pisa, Italy
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2014年 / 2卷 / 11期
关键词：
D O I：
10.1016/S2213-8587(14)70185-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：856 / 858
页数：4
相关论文
共 50 条
  • [41] Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature
    Lisco, Giuseppe
    De Tullio, Anna
    Guastamacchia, Edoardo
    Triggiani, Vincenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (04) : 626 - 646
  • [42] Titratable fixed-ratio vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on basal insulin
    Meier, J. J.
    Vidal, J.
    Liu, M.
    Perfetti, R.
    Rosenstock, J.
    DIABETOLOGIA, 2017, 60 : S372 - S372
  • [43] Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
    Gian Paolo Fadini
    Olga Disoteo
    Riccardo Candido
    Paolo Di Bartolo
    Luigi Laviola
    Agostino Consoli
    Diabetes Therapy, 2021, 12 : 781 - 800
  • [44] Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
    Fadini, Gian Paolo
    Disoteo, Olga
    Candido, Riccardo
    Di Bartolo, Paolo
    Laviola, Luigi
    Consoli, Agostino
    DIABETES THERAPY, 2021, 12 (03) : 781 - 800
  • [45] Online CME Improves Clinical Knowledge and Confidence Related to Use of GLP-1 Receptor Agonists in Combination with Basal Insulin
    Larkin, Amy
    Lacouture, Michael
    Le, Anne
    DIABETES, 2019, 68
  • [46] Impact of GLP-1 receptor agonist compared to basal insulin start on metabolic targets in patients living with type 2 diabetes and chronic kidney disease (Impact GLP-1 CKD)
    Ming, Y.
    Bradley, R.
    Auerbach, P.
    Abitbol, A.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S340 - S341
  • [47] Basal insulin or longacting GLP-1 receptor agonists-making the right choice
    Bloomgarden, Zachary T.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (06): : 439 - +
  • [48] Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes
    Blonde, Lawrence
    Anderson, John E.
    Chava, Pavan
    Dendy, Jared A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 793 - 804
  • [49] Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway
    Huetson, Pernilla
    Palmer, James L.
    Levorsen, Andree
    Fournier, Marie
    Germe, Maeva
    McLeod, Euan
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 573 - 585
  • [50] Deorphanisation of black widow spider GLP-1: validation of GLP-1 receptor agonist action relevant to human islet insulin secretion in vitro
    Holz, G. G.
    Liles, A. N.
    Doyle, R. P.
    Leech, C. A.
    Chepurny, O. G.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S294 - S295
12345